Home Treatment News FDA Gives Nod to Calquence for Mantle Cell Lymphoma Treatment

FDA Gives Nod to Calquence for Mantle Cell Lymphoma Treatment

SHARE

The U.S. Food and Drug Administration on October 31, 2017, approved limited use of Calquence for treatment of adults suffering from mantle cell lymphoma.

To qualify for treatment with Calquence, the patient must have received at least one prior therapy.

Mantle cell lymphoma (also known as MCL) most often affects men over the age of 60.  Lymphoma is the most common type of blood cancer, consisting of two primary forms — Hodgkin lymphoma and non-Hodgkin lymphoma.

Lymphoma occurs when lymphocytes, cells of the immune system, grow uncontrollably and travel to parts of the body forming tumors.  The body has two main types of lymphomas — B-lymphocytes (B-Cells) and T-lymphocytes (T-cells).  Mantle cell lymphoma is among the B-cell lymphoma and can be fast growing.

Mantle cell lymphoma is estimated to comprise 3 to 10 percent of all non-Hodgkin lymphoma cases in the U.S.

Calquence blocks kinase, an enzyme which otherwise assists the cancer to multiply and spread.

SLN Sources:  FDA Press Release Dated Oct. 31, 2017Resource Material from Lymphoma Research Foundation.